<- Go Home

Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Market Cap

$10.8B

Volume

790.2K

Cash and Equivalents

$480.4M

EBITDA

$602.0M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$2.1B

Profit Margin

71.01%

52 Week High

$354.88

52 Week Low

$145.59

Dividend

N/A

Price / Book Value

8.33

Price / Earnings

36.51

Price / Tangible Book Value

9.55

Enterprise Value

$11.4B

Enterprise Value / EBITDA

18.55

Operating Income

$507.1M

Return on Equity

23.00%

Return on Assets

9.75

Cash and Short Term Investments

$480.4M

Debt

$1.0B

Equity

$1.3B

Revenue

$2.9B

Unlevered FCF

$293.9M

Sector

Health Care Equipment and Supplies

Category

N/A

Company Stock Pitches